Premium
Continuous venovenous hemodialysis may be effective in digoxin removal in digoxin toxicity: A case report
Author(s) -
Gokalp Cenk,
Dogan Aysun Fatma,
Aygun Guray,
Kurultak Ilhan,
Ustundag Sedat
Publication year - 2020
Publication title -
hemodialysis international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.658
H-Index - 47
eISSN - 1542-4758
pISSN - 1492-7535
DOI - 10.1111/hdi.12867
Subject(s) - digoxin , medicine , hemodialysis , heart failure , dialysis , hyperkalemia , toxicity , hypervolemia , atrial fibrillation , cardiology , antidote , peritoneal dialysis , anesthesia , blood volume
Digoxin is a cardiac glycoside that is used for the treatment of heart failure and atrial fibrillation. Besides its careful close follow‐up, toxicity affects nearly 1% of congestive heart failure patients. Cessation of the drug, appropriate electrolyte and rhythm control and digoxin‐Fab antibody are the mainstay for toxicity treatment in these patients. As known, hemodialysis and peritoneal dialysis are not effective by the means of digoxin removal. We present a 66‐year‐old patient who admitted to hospital with digoxin toxicity and severe acute kidney injury. The patient was treated with continuous venovenous hemodialysis because of her hypervolemia, hyperkalemia, cardiac instability, and the thought of probable decrease in digoxin levels concerning the continuous nature of solute clearance. Without the treatment using digoxin‐specific Fab antibodies, the patient's digoxin level was decreased successfully with continuous venovenous hemodialysis. In conclusion, continuous venovenous hemodialysis may be a treatment option in digoxin toxicity especially those who suffer from severe renal dysfunction and cannot access digoxin antidote.